Literature DB >> 9060691

Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin).

O Pleskoff1, N Sol, B Labrosse, M Alizon.   

Abstract

A clade B strain of human immunodeficiency virus type 1 (HIV-1(LAI)) could infect CD4+ cells expressing human CXCR-4 (fusin) or its rat homolog with similar efficacy. By contrast, cells expressing rat CXCR-4 were not permissive to HIV-1(NDK) (clade D), HIV-2(ROD), or HIV-1(LAI) with chimeric envelope protein gp120 bearing the V3 domain from HIV-1(NDK). The reciprocal chimeric gp120 (HIV-1(NDK) with V3 from HIV-1(LAI)) could mediate infection of cells expressing either human or rat CXCR-4. Genetically divergent HIV strains have different requirements for interaction with the CXCR-4 coreceptor, and the gp120 V3 domain seems to be involved in this interaction.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9060691      PMCID： PMC191460     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  The molecular biology of leukocyte chemoattractant receptors.

Authors:  P M Murphy
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 2.  HIV-1 virion-cell interactions: an electrostatic model of pathogenicity and syncytium formation.

Authors:  L Callahan
Journal:  AIDS Res Hum Retroviruses       Date:  1994-03       Impact factor: 2.205

3.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.

Authors:  C C Bleul; M Farzan; H Choe; C Parolin; I Clark-Lewis; J Sodroski; T A Springer
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

4.  Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.

Authors:  M Loetscher; T Geiser; T O'Reilly; R Zwahlen; M Baggiolini; B Moser
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

5.  Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line.

Authors:  R D Harrington; A P Geballe
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s).

Authors:  C C Broder; D S Dimitrov; R Blumenthal; E A Berger
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

7.  Fusion from without directed by human immunodeficiency virus particles.

Authors:  F Clavel; P Charneau
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection.

Authors:  P Lorès; V Boucher; C Mackay; M Pla; H Von Boehmer; J Jami; F Barré-Sinoussi; J C Weill
Journal:  AIDS Res Hum Retroviruses       Date:  1992-12       Impact factor: 2.205

9.  Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein.

Authors:  O Schwartz; M Alizon; J M Heard; O Danos
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

10.  A rodent cell line permissive for entry and reverse transcription of human immunodeficiency virus type 1 has a pre-integration block to productive infection.

Authors:  J H Simon; G A Schockmel; P Illei; W James
Journal:  J Gen Virol       Date:  1994-10       Impact factor: 3.891
View more
  27 in total

1.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication.

Authors:  D Camerini; H P Su; G Gamez-Torre; M L Johnson; J A Zack; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 5.  In vitro methods in the study of viral and prion permeability across the blood-brain barrier.

Authors:  Ryota Nakaoke; William A Banks
Journal:  Cell Mol Neurobiol       Date:  2005-02       Impact factor: 5.046

6.  Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons.

Authors:  S B Oh; P B Tran; S E Gillard; R W Hurley; D L Hammond; R J Miller
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

7.  Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.

Authors:  K E Follis; M Trahey; R A LaCasse; J H Nunberg
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

8.  The cytomegalovirus-encoded chemokine receptor US28 can enhance cell-cell fusion mediated by different viral proteins.

Authors:  O Pleskoff; C Tréboute; M Alizon
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

9.  Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity.

Authors:  A Brelot; N Heveker; O Pleskoff; N Sol; M Alizon
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

10.  Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.

Authors:  M Moulard; H Lortat-Jacob; I Mondor; G Roca; R Wyatt; J Sodroski; L Zhao; W Olson; P D Kwong; Q J Sattentau
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.